Home Cart Sign in  
Chemical Structure| 937263-43-9 Chemical Structure| 937263-43-9

Structure of Tucatinib
CAS No.: 937263-43-9

Chemical Structure| 937263-43-9

Tucatinib

CAS No.: 937263-43-9

Irbinitinib is a potent and selectiveHER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold selective forHER2 versus EGFR.

4.5 *For Research Use Only !

Cat. No.: A100992 Purity: 98%

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łÇǶÊÊ Inquiry Inquiry
5mg łÇò¶ÊÊ Inquiry Inquiry
10mg łË˶ÊÊ Inquiry Inquiry
25mg ł§§¶ÊÊ Inquiry Inquiry
100mg łóď¶ÊÊ Inquiry Inquiry
250mg łÇÍď¶ÊÊ Inquiry Inquiry
1g ł§îď¶ÊÊ Inquiry Inquiry
5g łÇ§óî¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1mg

    łÇǶÊÊ

  • 5mg

    łÇò¶ÊÊ

  • 10mg

    łË˶ÊÊ

  • 25mg

    ł§§¶ÊÊ

  • 100mg

    łóď¶ÊÊ

  • 250mg

    łÇÍď¶ÊÊ

  • 1g

    ł§îď¶ÊÊ

  • 5g

    łÇ§óî¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tucatinib

CAS No. :937263-43-9
Formula : C26H24N8O2
M.W : 480.52
SMILES Code : CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC5=CC6=NC=NN6C=C5
InChI Key :SDEAXTCZPQIFQM-UHFFFAOYSA-N
Pubchem ID :51039094

Safety of Tucatinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Tucatinib

RTK

Isoform Comparison

Biological Activity

Target
  • HER2/ErbB2

    ErbB2, IC50:8 nM

  • HER2

    ErbB2, IC50:8 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MDCKII cells 1 µM 1 hour To determine the passive transcellular permeability and interaction with ABCB1 and ABCG2 for Tucatinib PMC9357092
HaCaT cells 1 µM, 2.5 µM 1 hour To assess the efficacy of tucatinib in inhibiting ErbB2 phosphorylation, results showed that tucatinib effectively inhibited ErbB2 phosphorylation, particularly at Y877 and Y1221/1222 sites. PMC10869470
BT474-Br 0 to 200 nM 4 days To evaluate the effect of combined tucatinib and trastuzumab treatment on the proliferation of HER2+ breast cancer brain metastasis cells. The results showed that the combination therapy significantly inhibited tumor cell proliferation. PMC8740706
AU565 0 to 200 nM 4 days To evaluate the effect of combined tucatinib and trastuzumab treatment on the proliferation of HER2+ breast cancer brain metastasis cells. The results showed that the combination therapy significantly inhibited tumor cell proliferation. PMC8740706
BT474 10 nM 72 hours Tucatinib significantly reduced the metabolic activity of HER2-overexpressing BT474 cells and enhanced the effects of radiation therapy. PMC11302197
ZR7530 10 nM 72 hours Tucatinib significantly reduced the metabolic activity of HER2-overexpressing ZR7530 cells and enhanced the effects of radiation therapy. PMC11302197
HCC1954 1 µM 72 hours Tucatinib significantly reduced the metabolic activity of HER2-overexpressing HCC1954 cells and enhanced the effects of radiation therapy. PMC11302197
SKBR3 cells 100 nM To evaluate the inhibitory effect of Tucatinib on HER2+ breast cancer cells, results showed that NF1-deficient cells exhibited resistance to Tucatinib. PMC8602441
HCC1954 cells 2 µM To evaluate the inhibitory effect of Tucatinib on HER2+ breast cancer cells, results showed that NF1-deficient cells exhibited resistance to Tucatinib. PMC8602441

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Orthotopic patient-derived xenografts of HER2+ breast cancer brain metastases Oral 75 mg/kg Twice daily for several weeks To evaluate the efficacy of combined treatment with tucatinib and abemaciclib in HER2+ breast cancer brain metastasis models, the results showed that the combined treatment significantly inhibited tumor growth and prolonged mouse survival. PMC8933392
Mice BT-474 xenograft model Oral 1 mg/kg Daily for four weeks To evaluate the therapeutic effect of MEK inhibitor on HER2+ breast cancer, results showed that NF1-deficient tumors exhibited a partial response to MEK inhibition. PMC8602441
Nude mice LS180-HER2 cell line-derived xenograft model Intravenous injection 10 mg/kg Administered on day 1, 7, and 21 Trastuzumab deruxtecan significantly delayed tumor progression and prolonged survival in the LS180-HER2 cell line-derived xenograft model. PMC11018475
MMTV-Balb/c and FVB/N mice HER2-positive breast cancer models Oral 25, 50, or 100 mg/kg Once daily for 100 days or to ethical limits Tucatinib significantly inhibited tumor growth in both models and demonstrated dose-dependent efficacy, and combination with PD-1 or PD-L1 inhibitors significantly improved survival in mice PMC10323890
Nude mice HER2+ breast cancer brain metastasis model Oral 20 mg/kg Once daily for 21 consecutive days To evaluate the effect of combined tucatinib and LM008-HER2Ab neural stem cell therapy on the survival of mice with HER2+ breast cancer brain metastasis. The results showed that the combination therapy significantly prolonged the survival of mice. PMC8740706

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05382364 Metastatic HER2+ Advanced Brea... More >>st Cancer|Breast Neoplasms|Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)|Colorectal Cancer Less << PHASE1 ACTIVE_NOT_RECRUITING 2025-12-29 Harbin Medical University Canc... More >>er Hospital-oncology of department ( Site 0010), Harbin, Heilongjiang, 150000, China|Hunan Cancer Hospital-Digestion and Urology ( Site 0008), Changsha, Hunan, 421000, China|Jilin Cancer Hospital-oncology department ( Site 0007), Changchun, Jilin, 130012, China|Fudan University Shanghai Cancer Center-Oncology ( Site 0001), Shanghai, Shanghai, 200032, China|Tianjin Medical University Cancer Institute and Hospital-Gastric oncology ( Site 0005), Tianjin, Tianjin, 300060, China Less <<
NCT03914755 Healthy PHASE1 COMPLETED 2019-08-04 PAREXEL International, Early P... More >>hase Clinical Unit - Los Angeles, Glendale, California, 91206, United States Less <<
NCT05892068 Metastatic Breast Cancer PHASE2 RECRUITING 2028-05-09 Memorial Sloan Kettering Cance... More >>r Center (Limited Protocol Activities), Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, 07645, United States|Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, 11553, United States Less <<
NCT04896320 Breast Cancer Stage IV PHASE1|PHASE2 WITHDRAWN 2023-06-19 Providence Cancer Institute - ... More >>Clackamas Clinic, Clackamas, Oregon, 97015, United States|Providence Newberg Medical Center, Newberg, Oregon, 97132, United States|Portland Providence Medical Center, Portland, Oregon, 97213, United States|Providence St. Vincent Medical Center, Portland, Oregon, 97225, United States Less <<
NCT03424473 - NO_LONGER_AVAILABLE - -
NCT03722823 Hepatic Impairment PHASE1 COMPLETED 2019-05-07 Orange County Research Center,... More >> Tustin, California, 92780, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States|NOCCR Knoxville and Volunteer Research Group, Knoxville, Tennessee, 37920, United States|Texas Liver Institute, San Antonio, Texas, 78215, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.08mL

0.42mL

0.21mL

10.41mL

2.08mL

1.04mL

20.81mL

4.16mL

2.08mL

 

Historical Records

Categories